STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

STAT PlusBiotech FDA expert committee reviews Capricor Therapeutics’ Duchenne drug Therapy has been closely watched by patient community, investors Manage alerts for this article Email this article Share this article By Adam Feuerstein and Andrew JosephJuly 29, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent.

You can reach Andrew confidentially on Signal at drewqjoseph.71. Welcome to STAT’s live blog coverage of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meeting, which on Wednesday will be reviewing deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The stakes are rather high.

Capricor has positioned deramiocel as one of the only treatment options for teenagers and young men with Duchenne who have already lost their ability to walk. In a Phase 3 study, deramiocel preserved upper-arm function and staved off the heart failure most patients eventually experience, Capricor said last December, achieving the primary and secondary goals of the trial with statistical significance. Advertisement The FDA, in a harshly critical review posted publicly on Monday, disagreed with the company’s conclusions.

In its own analysis, deramiocel failed to separate from placebo on the upper-limb and cardiac function endpoints, agency reviewers concluded. Furthermore, Capricor made numerous changes to the deramiocel study’s statistical analysis plan after it was completed, further muddying the outcome, the FDA said. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, FDA, Pharmaceuticals, rare diseases, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.

He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent.

You can reach Andrew confidentially on Signal at drewqjoseph.71. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended First Opinion July 29, 2026 The VA could help America win the biotechnology race with China Biotech July 29, 2026 STAT Plus: In the biotech industry, a most-wanted fugitive was long hiding in plain sight Advertisement Biotech July 28, 2026 STAT Plus: FDA staff reiterate concerns about Replimune skin cancer treatment Biotech July 28, 2026 STAT Plus: Preliminary trial results suggest a path to a safer Alzheimer’s treatment Health July 28, 2026 STAT Plus: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD Subscriber Picks